Content

List volumes - List articles in this issue

Clinical Report

Treatment of Autoimmune Urticaria with Low-dose Cyclosporin A: A One-year Follow-up

doi: 10.2340/00015555-0939

Abstract:

Patients with autoimmune urticaria (AIU) and positive autologous serum skin test (ASST) represent a more serious type of chronic urticaria that does not respond to treatment with antihistamines, but responds completely to systemic corticosteroids. Because of the chronic course of the disease, there is a risk of side-effects. Cyclosporin A (CsA) is an alternative treatment for patients with AIU. In order to determine the efficacy of CsA at the lowest possible dose in patients with chronic idiopathic urticaria and positive ASST, 30 patients were included in a 5-month study with a follow-up one year after the end of treatment. All patients had positive ASST before treatment and autoantibodies were present in 73%. Twenty-
three patients completed the study and responded to low-dose CsA treatment. Three patients did not respond to a dose of 2.5 mg/kg CsA, and 4 patients dropped-out due to side-effects. After the first month of treatment, an improvement of 31% was noted, reaching 88% after the fifth month of treatment. The mean dose of CsA was 2.16 mg/kg for the first month and 0.55 mg/kg for the fifth month. Three to 6 months after the end of the study, the ASST was repeated and was negative in 78.3% of patients. At the one-year follow-up, 20 patients were symptom-free (87%) and 3 had relapsed (13%). CsA,
even in low-doses, can be an effective and short-term treat-
ment with minimum side-effects in patients with AIU.

Authors:

Christine D. Boubouka, Christina Charissi, Dimitris Kouimintzis, Dimitris Kalogeromitros, Panagiotis G. Stavropoulos, Alexandra Katsarou

References

  • Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol 2007; 33: 134–143.
  • Matthews KP. The urticarias. Current concepts in pathogenesis and treatment. Drugs 1985; 30: 552–560.
  • Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34: 294–301.
  • Leiste A, Skaletz-Rorowdki A, Venten I, Altmeyer P, Brockmeyer NH. Urticaria associated with Norovirus infection: report of two cases. J Dtsch Dermatol Ges 2008; 6: 563–565.
  • Hachulla E. Les urticaires systemiques. Ann Dermatol Venereol 2003; 130: 553–568.
  • Brunetti L, Francavilla R, Miniello VL, Platzer MH, Rizzi D, Lospalluti ML, et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 2004; 114: 922–927.
  • Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol 2005; 5: 403–407.
  • Puccetti A, Bason C, Simeoni S, Millo E, Tinazzi E, Beri R, et al. In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005; 35: 1599–1607.
  • Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599–1604.
  • Dodig S, Richter D. Chronic autoimmune urticaria in children. Acta Dermatovenerol Croat 2008; 16: 65–71.
  • Elias J, Boss E, Kaplan AD. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986; 78: 914–918.
  • Ezeamuzie IC, Assem ES. Inhibition of histamine release from human lung and rat peritoneal mast cells by cyclosporine A. Agents Actions 1990; 30: 110–113.
  • Sabroe RA, Grattan CEH, Francis DM, Barr RM, Kobza Black A, Greaves MW. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446–453.
  • Dutz JP, Ho CV. Immunosuppressive agents in dermatology. An update. Dermatologic Clinics 1998; 16: 235–251.
  • Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114: 465–474.
  • Piconi S, Trabattoni D, Iemoli E, Fusi ML, Villa ML, Milazzo F, et al. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2002; 128: 59–66.
  • Madan V, Griffiths CEM. Systemic cyclosporine and tacrolimus in dermatology. Dermatologic Therapy 2007; 20: 239–250.
  • Stellato C, dePaulis A, Ciccarelli A. Anti-inflammatory effect of cyclosporine A on human skin mast cell. J Invest Dermatol 1992; 98: 800–804.
  • Kay MM. Autoimmunity and aging. Concepts Immunopathol 1988; 6: 166–192.
  • Tachikawa S, Kawamura T, Kawamura H, KandaY, Fujii Y, Matsumoto H, et al. Appearance of B220 low autoantibody-producing B-1 cells at neonatal and older stages in mice. Clin Exp Immunol 2008; 153: 448–455.
  • Zauli D, Grassi A, Ballardini G, Contestabile S, Zucchini S, Bianchi FB. Thyroid autoimmunity in chronic idiopathic urticaria. Am J Clin Dermatol 2002; 3: 525–528.
  • Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84: 66–71.
  • Sadighha A, Shirali R, Mohaghegh Z. Relationship between Helicobacter pylori and chronic urticaria. J Eur Acad Dermatol Venereol 2009; 23: 189–199.
  • Ryhal B, DeMera RS, Shoenfeld Y, Peter JB, Gershwin ME. Are autoantibodies present in patients with subacute and chronic urticaria? J Investig Allergol Clin Immunol 2001; 11: 16–20.
  • Inaloz HS, Ozturk S, Akcali C, Kirtak N, Tarakcioglu M. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol 2008; 35: 276–282.
  • Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P; 0–1–3 Study Group. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 55: 705–709.
  • Related articles

    There are no related articles.


    Share with your friends





    Actions


    Abstract

    Full text

    PDF

    Supplementary


    There is no supplementary for this article.

    Print information


    Volume 91, Issue 1

    DOI: 10.2340/00015555-0939

    Pages: 50-54

    View at PubMed